These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 36942294)

  • 21. The protease inhibitor cystatin C down-regulates the release of IL-β and TNF-α in lipopolysaccharide activated monocytes.
    Gren ST; Janciauskiene S; Sandeep S; Jonigk D; Kvist PH; Gerwien JG; Håkansson K; Grip O
    J Leukoc Biol; 2016 Oct; 100(4):811-822. PubMed ID: 27190304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease.
    Kooloos WM; de Jong DJ; Huizinga TW; Guchelaar HJ
    Drug Discov Today; 2007 Feb; 12(3-4):125-31. PubMed ID: 17275732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sinomenine Inhibits the Progression of Rheumatoid Arthritis by Regulating the Secretion of Inflammatory Cytokines and Monocyte/Macrophage Subsets.
    Liu W; Zhang Y; Zhu W; Ma C; Ruan J; Long H; Wang Y
    Front Immunol; 2018; 9():2228. PubMed ID: 30319663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology.
    Prandota J
    Am J Ther; 2005; 12(3):254-61. PubMed ID: 15891270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemokine and cytokine levels in inflammatory bowel disease patients.
    Singh UP; Singh NP; Murphy EA; Price RL; Fayad R; Nagarkatti M; Nagarkatti PS
    Cytokine; 2016 Jan; 77():44-9. PubMed ID: 26520877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disease-Drug Interactions in Inflammatory States via Effects on CYP-Mediated Drug Clearance.
    Coutant DE; Hall SD
    J Clin Pharmacol; 2018 Jul; 58(7):849-863. PubMed ID: 29505093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease.
    Schreiber S; Nikolaus S; Hampe J; Hämling J; Koop I; Groessner B; Lochs H; Raedler A
    Lancet; 1999 Feb; 353(9151):459-61. PubMed ID: 9989717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of infliximab on hepatic cytochrome P450 and pharmacokinetics of verapamil in rats with pre-adjuvant arthritis: a drug-disease and drug-drug interaction.
    Ling S; Jamali F
    Basic Clin Pharmacol Toxicol; 2009 Jul; 105(1):24-9. PubMed ID: 19371259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resolution of Crohn's disease.
    Schmitt H; Neufert C; Neurath MF; Atreya R
    Semin Immunopathol; 2019 Nov; 41(6):737-746. PubMed ID: 31552470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition Model.
    Ternant D; Pfister M; Le Tilly O; Mulleman D; Picon L; Willot S; Passot C; Bejan-Angoulvant T; Lecomte T; Paintaud G; Koch G
    Clin Pharmacokinet; 2022 Jan; 61(1):143-154. PubMed ID: 34351609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natalizumab for induction of remission in Crohn's disease.
    Macdonald JK; McDonald JW
    Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases.
    LaDuca JR; Gaspari AA
    Dermatol Clin; 2001 Oct; 19(4):617-35. PubMed ID: 11705350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-inflammatory Effect of Somatostatin Analogue Octreotide on Rheumatoid Arthritis Synoviocytes.
    Casnici C; Lattuada D; Crotta K; Truzzi MC; Corradini C; Ingegnoli F; Tonna N; Bianco F; Marelli O
    Inflammation; 2018 Oct; 41(5):1648-1660. PubMed ID: 29804189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Altered gene expression of hepatic cytochrome P450 in a rat model of intermittent hypoxia with emphysema.
    Yu H; Shao H; Wu Q; Sun X; Li L; Li K; Li X; Li Y; Zhang Q; Wu J; Chen H
    Mol Med Rep; 2017 Jul; 16(1):881-886. PubMed ID: 28560400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytochrome P450 Enzymes and Drug Metabolism in Humans.
    Zhao M; Ma J; Li M; Zhang Y; Jiang B; Zhao X; Huai C; Shen L; Zhang N; He L; Qin S
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.
    Siddiqui MA; Scott LJ
    Drugs; 2005; 65(15):2179-208. PubMed ID: 16225377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs.
    Alrubia S; Mao J; Chen Y; Barber J; Rostami-Hodjegan A
    Clin Pharmacokinet; 2022 Oct; 61(10):1365-1392. PubMed ID: 36056298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased proinflammatory cytokines in mesenteric fat in major surgery and Crohn's disease.
    Seifarth C; Hering NA; Arndt M; Lehmann KS; Stroux A; Weixler B; Kreis ME
    Surgery; 2021 Jun; 169(6):1328-1332. PubMed ID: 33431185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical pharmacokinetics and use of infliximab.
    Klotz U; Teml A; Schwab M
    Clin Pharmacokinet; 2007; 46(8):645-60. PubMed ID: 17655372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases.
    Siebert S; Tsoukas A; Robertson J; McInnes I
    Pharmacol Rev; 2015; 67(2):280-309. PubMed ID: 25697599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.